和黄医药2024年应占净收益3770万美元

财中社
19 Mar

3月19日,和黄医药(00013/HCM)发布2024年全年业绩及最新业务进展。报告显示,肿瘤产品市场销售额增长134%至5.01亿美元,得益于此,肿瘤产品的综合收入为2.71亿美元,增长65%。2024年和黄医药应占净收益为3770万美元,相较于2023年的1.01亿美元大幅下降,主要受研发支出和销售成本上升影响。管理层提到,肿瘤产品收入的显著增长主要得益于FRUZAQLA®在美国和其他市场的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10